PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
28039187-4	2017	METHODS: This was a post hoc analysis of patients with CTD-PAH and SSc-PAH from AMBITION, an event-driven, double-blind trial in patients with WHO functional class II/III PAH.	beta-cyclodextrin tetradecasulfate	55-58	phenylalanine hydroxylase	Homo sapiens	59-62	
25577565-8	2015	Among classic responders, 12 (60%) had IPAH and 8 (40%) had connective tissue disease-associated PAH (CTD-PAH); however, only responders with IPAH had improved survival compared with non-responders (p = 0.02).	beta-cyclodextrin tetradecasulfate	102-105	phenylalanine hydroxylase	Homo sapiens	97-100	
16831323-13	2006	CONCLUSIONS: PAH is a common complication of CTDs, which occurs often in the forth year after initial CTD manifestations and is earlier in patients with SLE or MCTD, compared to those with pSS.	beta-cyclodextrin tetradecasulfate	45-49	phenylalanine hydroxylase	Homo sapiens	13-16